Discovery analysed data from over 46 000 people who received the first dose of the Pfizer jab in Gauteng to see how much protection it offered. This local data also showed that people infected during the country’s second wave were at 65% lower risk of re-infection. Pfizer’s safety and efficacy trial showed that the jab was 95% efficacious in preventing Covid-19 of any severity in study participants who had not been infected with SARS-CoV-2 prior to vaccination. Discovery’s analysis focused on data from 46 007 vaccinated Discovery Health members - all of them lived in Gauteng - and studied how this group’s infections, hospitalisations and deaths compared to a matched clinical cohort of unvaccinated members. Discovery Health receives all its clients’ pathology PCR Covid test results on a daily basis from the laboratories.

Source: News 24 July 09, 2021 08:26 UTC